TargetBeta
CSF1R
colony stimulating factor 1 receptor · also M-CSF-R, C-FMS, CSFR, CD115 · CD molecules
6 programs in company-led studies act on CSF1R, from 6 companies: 5 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| axatilimabrule | Incyte | phase 3 | 127 running | – | NCIt |
| pimicotinibrule | Abbisko Cayman | phase 3 | 146 running | – | NCIt |
| quizartinibrule | Daiichi Sankyo | phase 3 | 225 running | FLT3, KIT, PDGFRA, PDGFRB, RET | ChEMBL |
| vimseltinibrule | Ono Pharmaceutical | phase 3 | 85 running | – | NCIt |
| seralutinibrule | GB002, Inc., a wholly owned subsidiary of Gossamer Bio | phase 3 | 82 running | KIT, PDGFRA, PDGFRB | ChEMBL |
| adrixetinibrule | Qurient | phase 2 | 32 running | AXL | NCIt |
Conditions their studies are in
- Bronchiolitis Obliterans Syndrome, 3 programs
- Giant Cell Tumor of Tendon Sheath, 2 programs
- Neoplasm Metastasis, 2 programs
- Synovitis, Pigmented Villonodular, 2 programs
- Coronavirus Infections, 1 program
- Esophageal Neoplasms, 1 program
- Hypertension, Pulmonary, 1 program
- Idiopathic Pulmonary Fibrosis, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026vimseltinib · Ono Pharmaceutical · phase 3 · NCT07744802
- Dec 2026seralutinib · GB002, Inc., a wholly owned subsidiary of Gossamer Bio · phase 3 · NCT06274801
- Jan 6, 2027axatilimab · Incyte · phase 3 · NCT06843408
- May 1, 2027quizartinib · Daiichi Sankyo · phase 3 · NCT03793478
- Dec 30, 2027adrixetinib · Qurient · phase 2 · NCT05438420
- Aug 22, 2028pimicotinib · Abbisko Cayman · phase 3 · NCT07499362
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.